<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804033</url>
  </required_header>
  <id_info>
    <org_study_id>BHV3500-302</org_study_id>
    <nct_id>NCT04804033</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention</brief_title>
  <official_title>A Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceutical Holding Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo&#xD;
      as a preventive treatment for migraine, as measured by the reduction in the number of&#xD;
      migraine days per month.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">September 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of zavegepant compared to placebo as a preventive treatment for migraine</measure>
    <time_frame>Number of migraine during weeks 9 to 12</time_frame>
    <description>Measured by the mean reduction from baseline (i.e., Observation Phase) in the number of migraine days per month in the last 4 weeks of the Double-blind Treatment Phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of zavegepant compared to placebo with the number of subjects that had a â‰¥ 50% reduction from baseline.</measure>
    <time_frame>Number of migraine days during weeks 9 to 12</time_frame>
    <description>Measured by the number of moderate to severe migraine days per month in the last 4 weeks of the double-blind treatment phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of zavegepant to placebo on mean reduction from baseline.</measure>
    <time_frame>Number of migraine days during per month during weeks 1 to 12</time_frame>
    <description>Measured by the number of migraine days per month over the entire Double-Blind Treatment Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of zavegepant to placebo on mean reduction from baseline.</measure>
    <time_frame>Number of migraine days per month during weeks 1 to 4</time_frame>
    <description>Measured by the number of migraine days per month in the first 4 weeks of the Double-Blind Treatment Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of zavegepant to placebo in the mean number of acute migraine specific medication days per month.</measure>
    <time_frame>Number of migraine days per month during weeks 1 to 12</time_frame>
    <description>Measured by the number of acute migraine specific medication days in the last 4 weeks of the Double-Blind Treatment Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of zavegepant.</measure>
    <time_frame>From Baseline through Week 12</time_frame>
    <description>This will be evaluated by the number of participants with treatment related adverse events by severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of ALT or AST elevations &gt; 3x ULN, concurrently with bilirubin elevations &gt; 2x ULN in subjects treated with zavegepent.</measure>
    <time_frame>From Baseline through Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of hepatic related adverse events.</measure>
    <time_frame>From Baseline through Week 12</time_frame>
    <description>Measured by discontinuations in subjects treated with zavegepant due to elevated Liver function Tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change from baseline in the Migraine-Specific Quality-of-Life Questionnaire v 2.1 (MSQ) role function.</measure>
    <time_frame>Week 12 of the double-blind treatment phase.</time_frame>
    <description>Measured by the restrictive domain score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change from baseline in the Migraine Disability Assessment (MIDAS).</measure>
    <time_frame>Week 12 of the double-blind treatment phase.</time_frame>
    <description>Measured by the Migraine Disability Assessment (MIDAS) total score.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2900</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>BHV-3500 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zavegepant 200mg oral soft gel capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 200mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 200mg oral soft gel capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BHV-3500 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zavegepant 100mg oral soft gel capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 100mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 100mg oral soft gel capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHV-3500 (zavegepant)</intervention_name>
    <description>BHV-3500 (zavegepant) softgel capsule.</description>
    <arm_group_label>BHV-3500 100mg</arm_group_label>
    <arm_group_label>BHV-3500 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo softgel capsule.</description>
    <arm_group_label>Placebo 100mg</arm_group_label>
    <arm_group_label>Placebo 200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject has at least 1 year history of migraine (with or without aura) consistent with a&#xD;
        diagnosis according to the International Classification of&#xD;
&#xD;
        Headache Disorders, 3rd Edition, including the following:&#xD;
&#xD;
          1. Age of onset of migraines prior to 50 years of age&#xD;
&#xD;
          2. Migraine attacks, on average, lasting 4 - 72 hours if untreated&#xD;
&#xD;
          3. Per subject report, 4 - 18 migraine attacks of moderate to severe intensity per month&#xD;
             within the last 3 months prior to the Screening Visit&#xD;
&#xD;
          4. Six or more migraine days during the Observation Period&#xD;
&#xD;
          5. Not more than 18 headache days during the Observation Period&#xD;
&#xD;
          6. Ability to distinguish migraine attacks from tension/cluster headaches&#xD;
&#xD;
          7. Subjects on prophylactic migraine medication are permitted to remain on 1 medication&#xD;
             with possible migraine-prophylactic effects if the dose has been stable for at least 3&#xD;
             months prior to the Screening Visit, and the dose is not expected to change during the&#xD;
             course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with a history of HIV disease&#xD;
&#xD;
          2. Subject history with current evidence of uncontrolled, unstable or recently diagnosed&#xD;
             cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and&#xD;
             cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome&#xD;
             (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient&#xD;
             ischemic attack (TIA) during the 6 months prior to screening&#xD;
&#xD;
          3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however&#xD;
             subjects can be included who have stable hypertension and/or diabetes for at least 3&#xD;
             months prior to screening).&#xD;
&#xD;
          4. Subjects with major depressive episode or anxiety disorder which require more than 1&#xD;
             daily medication for each disorder or subjects with a major depressive episode within&#xD;
             the last 12 months. Medications to treat major depressive disorder or an anxiety&#xD;
             disorder must have been at a stable dose for at least 3 months prior to the Screening&#xD;
             Visit.&#xD;
&#xD;
          5. Subjects with active chronic pain syndromes (including trigeminal neuralgia),&#xD;
             psychiatric conditions, dementia, or significant neurological disorders (other than&#xD;
             migraine) that, in the Investigator's opinion interfere with study assessments of&#xD;
             safety or efficacy.&#xD;
&#xD;
          6. Subject has a history of gastric, or small intestinal surgery (including Gastric&#xD;
             Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease or&#xD;
             condition (e.g. chronic pancreatitis, ulcerative colitis, etc.) that causes&#xD;
             malabsorption.&#xD;
&#xD;
          7. Body mass index &gt; 33 kg/m2&#xD;
&#xD;
          8. History of gallstones or cholecystectomy.&#xD;
&#xD;
          9. The subject has a history or current evidence of any unstable medical conditions&#xD;
             (e.g., history of congenital heart disease or arrhythmia, known or suspected&#xD;
             infection, hepatitis B or C, or cancer) that, in the investigator's opinion, would&#xD;
             expose them to undue risk of a significant adverse event (AE) or interfere with&#xD;
             assessments of safety or efficacy during the course of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elyse Stock, MD</last_name>
    <phone>203-404-0410</phone>
    <email>clinicaltrials@biohavenpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Velocity San Diego</last_name>
      <phone>619-704-2750</phone>
      <email>info@velocityclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Manivanh</last_name>
      <phone>619-303-6130</phone>
      <email>manivanhs@synergysandiego.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Cabral</last_name>
      <phone>562-304-1742</phone>
      <email>annecabral@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Med. Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Rickers</last_name>
      <phone>818-990-2671</phone>
      <email>stacey@cnrmg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ki Health Partners, LLC, dba New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sydney Katz</last_name>
      <phone>203-914-1903</phone>
      <email>Sydney@neinh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Angel</last_name>
      <phone>904-281-5757</phone>
      <email>sangel@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates, Inc.</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Tirella</last_name>
      <phone>386-438-8977</phone>
      <email>emmat@msrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc. dba CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Letitia Griffin</last_name>
      <phone>407-425-5100</phone>
      <email>lgriffin@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Deluca</last_name>
      <phone>813-264-2155</phone>
      <email>bdeluca@forcaremed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSV Clinical Researh Study, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Villanueva</last_name>
      <phone>813-200-6007</phone>
      <email>soniav@jsvclinrs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kayla Sutrgeon</last_name>
      <phone>712-639-6300</phone>
      <email>kmelbie@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC.</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Thome</last_name>
      <phone>316-689-6629</phone>
      <email>cindy.thome@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC.</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Thomas</last_name>
      <phone>316-804-7303</phone>
      <email>shannon.thomas@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jordan Danby</last_name>
      <phone>316-462-0423</phone>
      <email>jordan.danby@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivia Kelly</last_name>
      <phone>502-214-3990</phone>
      <email>okelly@lmarc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crescent City Headache and Neurology</name>
      <address>
        <city>Chalmette</city>
        <state>Louisiana</state>
        <zip>70043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Terre</last_name>
      <phone>504-418-6040</phone>
      <email>donna@neinh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caitlin Simon</last_name>
      <phone>504-336-2667</phone>
      <email>csimon@delricht.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Gannon</last_name>
      <phone>617-477-4868</phone>
      <email>julie@bostontrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Netword</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Todd-Seymour</last_name>
      <phone>508-320-9248</phone>
      <email>Ktoddseymour@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medvadis Research Coroporation</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donald Counihan</last_name>
      <phone>617-744-1310</phone>
      <email>dcounihan@medvadis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Head Pain and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana Rus</last_name>
      <phone>734-677-6000</phone>
      <phone_ext>215</phone_ext>
      <email>drus@mhni.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Resarch Institiute, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Hunt</last_name>
      <phone>612-333-2200</phone>
      <phone_ext>370</phone_ext>
      <email>Elizabeth.devere.hunt@CRIminnesota.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Smith</last_name>
      <phone>636-387-5100</phone>
      <email>tsmith@studymetrix.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinvest Research, LLC.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brittni Kendrick</last_name>
      <phone>417-883-7889</phone>
      <email>bkendrick@clinvest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Harper</last_name>
      <phone>402-371-0797</phone>
      <email>charper@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center: Headache Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Sun</last_name>
      <phone>929-263-3831</phone>
      <email>dansun@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central New York Clinical Research</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renee Barbato</last_name>
      <phone>315-427-4906</phone>
      <email>rbarbato@cnycr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Headache Wellness Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Casey Roberts</last_name>
      <phone>336-574-8001</phone>
      <email>croberts@headachewellnesscenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Schuch</last_name>
      <phone>919-783-4895</phone>
      <email>katherine.schuch@accellacare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Courtney Boyce</last_name>
      <phone>910-799-5500</phone>
      <email>courtney.boyce@accellacare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Mobberley-Schuman</last_name>
      <phone>513-598-9290</phone>
      <email>pmobberleyschuman@citifacts.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Zhu</last_name>
      <phone>513-206-9991</phone>
      <email>mzhu@hometownurgentcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research-Clintonville</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ritu Singia</last_name>
      <phone>614-745-8863</phone>
      <email>rsingia@hometownurgentcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Singia Ritu</last_name>
      <phone>937-912-4367</phone>
      <email>rsingia@hometownurgentcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hightower Clinical</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan Whitson</last_name>
      <phone>405-479-8331</phone>
      <email>megan@hightowerclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon) Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tawyna Anderson</last_name>
      <phone>503-972-9803</phone>
      <email>tanderson@summitnetwork.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Philadelphia, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aneesh Vaze</last_name>
      <phone>215-676-6696</phone>
      <email>aneesh@phillyresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tower Health Medical Group - Neurology</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renee McLin</last_name>
      <phone>484-628-8928</phone>
      <email>renee.mclin@towerhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Taylor</last_name>
      <phone>843-856-3784</phone>
      <email>staylor@coastalcarolinaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Iskiwitz</last_name>
      <phone>901-843-1045</phone>
      <email>kiskiwitz@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin Ashmore</last_name>
      <phone>214-369-2600</phone>
      <email>erina@fstrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Star Research, LLC.</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashlynn Morton</last_name>
      <phone>979-529-9440</phone>
      <email>ashlynn.redstarresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zohair Harianawala</last_name>
      <phone>281-517-0550</phone>
      <email>zohair@dmclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research, LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen George</last_name>
      <phone>801-288-0607</phone>
      <email>kgeorge@wasatchcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc.</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Gular</last_name>
      <phone>757-591-8100</phone>
      <email>cqgular@hrhr-inc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Women's: Heal, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Barragan</last_name>
      <phone>206-522-3330</phone>
      <phone_ext>113</phone_ext>
      <email>dbarragan@seattlewomens.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine Prevention</keyword>
  <keyword>Phonophobia</keyword>
  <keyword>Photophobia</keyword>
  <keyword>Nausea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

